COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease - PubMed (original) (raw)
Review
COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease
Kam Wa Chan et al. Am J Chin Med. 2020.
Abstract
As of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7-10% and median time to intensive care admission is 9.5-10.5 days with mortality of around 1-2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest in silico findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese medicine could be considered as an adjunctive therapeutic option in the management of COVID-19.
Keywords: 2019-nCoV; COVID-19; Chinese Medicine; Guideline; Integrative Medicine; Review.
Similar articles
- [A single arm clinical study of 86 patients with common type of coronavirus disease 2019 treated by integrated traditional Chinese and Western medicine: multicenter case observation from 7 designated hospitals in Henan Province].
Xie Y, Wang J, Li S, Fu L, Sun J, Zhao J, Zhang H, Jia K, Zhao Q, Li B, Li J. Xie Y, et al. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Aug;32(8):922-927. doi: 10.3760/cma.j.cn121430-20200528-00485. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32912403 Chinese. - Clinical features and treatment of COVID-19 patients in northeast Chongqing.
Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong Y, Huang X, Lv J, Luo Y, Shen L, Yang H, Huang G, Yang R. Wan S, et al. J Med Virol. 2020 Jul;92(7):797-806. doi: 10.1002/jmv.25783. Epub 2020 Apr 1. J Med Virol. 2020. PMID: 32198776 Free PMC article. - Clinical characteristics of coronavirus disease 2019 in Gansu province, China.
Yue H, Bai X, Wang J, Yu Q, Liu W, Pu J, Wang X, Hu J, Xu D, Li X, Kang N, Li L, Lu W, Feng T, Ding L, Li X, Qi X; Gansu Provincial Medical Treatment Expert Group of COVID-19. Yue H, et al. Ann Palliat Med. 2020 Jul;9(4):1404-1412. doi: 10.21037/apm-20-887. Epub 2020 Jul 13. Ann Palliat Med. 2020. PMID: 32692208 - SARS-CoV-2 and COVID-19: How much do we know?
Wang M, Liao Z. Wang M, et al. Acta Virol. 2020;64(3):288-296. doi: 10.4149/av_2020_301. Acta Virol. 2020. PMID: 32985201 Review. - Becoming a Faithful Defender: Traditional Chinese Medicine against Coronavirus Disease 2019 (COVID-19).
Zhang L, Yu J, Zhou Y, Shen M, Sun L. Zhang L, et al. Am J Chin Med. 2020;48(4):763-777. doi: 10.1142/S0192415X2050038X. Epub 2020 Apr 29. Am J Chin Med. 2020. PMID: 32349517 Review.
Cited by
- Meaningful activities during COVID-19 lockdown and association with mental health in Belgian adults.
Cruyt E, De Vriendt P, De Letter M, Vlerick P, Calders P, De Pauw R, Oostra K, Rodriguez-Bailón M, Szmalec A, Merchán-Baeza JA, Fernández-Solano AJ, Vidaña-Moya L, Van de Velde D. Cruyt E, et al. BMC Public Health. 2021 Mar 30;21(1):622. doi: 10.1186/s12889-021-10673-4. BMC Public Health. 2021. PMID: 33785029 Free PMC article. - Smoking and COVID-19: Adding Fuel to the Flame.
Kashyap VK, Dhasmana A, Massey A, Kotnala S, Zafar N, Jaggi M, Yallapu MM, Chauhan SC. Kashyap VK, et al. Int J Mol Sci. 2020 Sep 9;21(18):6581. doi: 10.3390/ijms21186581. Int J Mol Sci. 2020. PMID: 32916821 Free PMC article. Review. - Add-on Ayurveda Treatment for Early Stage COVID-19: A Single Center Retrospective Cohort Study From Gujarat, India.
Thakar A, Panara K, Patel F, Bhagiya S, Goyal M, Bhinde S, Chaudhari S, Chaturvedi S. Thakar A, et al. J Evid Based Integr Med. 2021 Jan-Dec;26:2515690X211020685. doi: 10.1177/2515690X211020685. J Evid Based Integr Med. 2021. PMID: 34057365 Free PMC article. - Effects of Short-Term Low-Dose Glucocorticoids for Patients with Mild COVID-19.
Fu HY, Luo Y, Gao JP, Wang L, Li HJ, Li X, Xue L, Tang XQ, Li HW, Du YR. Fu HY, et al. Biomed Res Int. 2020 Sep 23;2020:2854186. doi: 10.1155/2020/2854186. eCollection 2020. Biomed Res Int. 2020. PMID: 33015160 Free PMC article. - Some natural hypomethylating agents in food, water and environment are against distribution and risks of COVID-19 pandemic: Results of a big-data research.
Besharati MR, Izadi M, Talebpour A. Besharati MR, et al. Avicenna J Phytomed. 2022 May-Jun;12(3):309-324. doi: 10.22038/AJP.2022.19520. Avicenna J Phytomed. 2022. PMID: 36186929 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous